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Abstract 
Introduction 
Anaphylaxis is responsible for considerable morbidity and it may in some cases prove fatal.  
Areas covered 
This review summarises the findings from recent studies on the epidemiology and aetiology of 
anaphylaxis and draws on the insights from this work and recent international guidelines to consider the 
implications for clinical care. Acute management of anaphylaxis is centred on early recognition, treatment 
with adrenaline (epinephrine) and other essential life-support measures.  The importance of longer-term 
care of patients with a history of or at risk of anaphylaxis are also considered with a view to minimising 
the risk of further reactions and decreasing the severity and impact of these reactions.  Tailored individual 
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anaphylaxis management plans should be a routine component of this longer-term care with provision of 
adrenaline auto-injectors to those at risk of further episodes of anaphylaxis.  More generally, there is a 
need to ensure that there are standard protocols in place to ensure that risks of triggering anaphylaxis are 
minimised and appropriate acute and long-term care are provided if reactions occur. 
Expert commentary 
It is important to be aware that anaphylaxis may occur in patients of any age, sex or ethnicity.  Early 
recognition and prompt treatment with adrenaline are potentially life-saving.  Careful assessment of risk 
and appropriate long-term management are key to improving long-term outcomes in those at risk of 
repeat episodes of anaphylaxis. 
 
Keywords: adrenaline; allergy; anaphylaxis; hypersensitivity; guidelines; incidence; self-management  
 
1. Introduction 
Anaphylaxis is an acute, potentially life-threatening systemic hypersensitivity reaction. This article aims to 
provide a synopsis of the evidence on its epidemiology, aetiology and clinical management.  We draw in 
particular on the findings from international guidelines to provide recommendations on both the acute 
and longer-term management of anaphylaxis.1 2 3 In so doing, our focus is on providing information and 
insights that will be of direct relevance both in the context of providing effective emergency care and to 
reduce the risk of further reactions.  We begin by reviewing definitions and the key clinical features of 
anaphylaxis. 
 
2. Defining anaphylaxis  
Anaphylaxis has been defined as a “severe, life-threatening generalized or systemic hypersensitivity reaction,” 4 5 which 
may prove fatal through cardiovascular and/or respiratory compromise.  Reactions are most commonly 
IgE-mediated involving allergen exposure, which triggers release of a range of inflammatory mediators 
from mast cells and basophils.  Other non-IgE mediated pathophysiological mechanisms have also been 
described, particularly in relation to drug triggered anaphylaxis.6 7  Previously, there was a distinction 
made between what were sometimes described as IgE-mediated ‘anaphylactic’ reactions and non-IgE-
mediated ‘anaphylactoid’ reactions; however, given that the emergency management of these reactions is 
identical this nomenclature is no longer in clinical use.  In keeping with this convention, we will use the 
term anaphylaxis in the remainder of this article. 
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Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled: 
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula) 
AND AT LEAST ONE OF THE FOLLOWING 
a. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia) 
b. Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia 
[collapse], syncope, incontinence). 
 
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that 
patient (minutes to several hours): Involvement of the skin-mucosal tissue (eg, generalized 
hives, itch-flush, swollen lips-tongue-uvula) 
a. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia) 
b. Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, incontinence) 
c. Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting). 
 
3. Reduced BP after exposure to known allergen for that patient (minutes to several hours): 
a. Infants and children: low systolic BP (age specific) or greater than 30% decrease in 
systolic BP* 
b. Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from that 
person’s baseline 
3. Clinical features 
The signs and symptoms of anaphylaxis are wide-ranging, involving multiple organ systems (see Box 1).  
The vast majority of reactions have an acute onset – typically within seconds or minutes – but slower 
courses of reaction over an hour or two may sometimes occur.  This can lead to difficulty and delay in the 
prompt diagnosis of anaphylaxis, particularly with the first episode, as a range of differential diagnoses 
may need to be considered (see Box 2). Signs and symptoms suggesting compromise of either the 
respiratory or cardiovascular system or both should be particularly noted as fatalities arise from failure of 
one or both of these systems.8 It should be noted that the presence of shock is not mandatory for the 
diagnosis of anaphylaxis; indeed, it is absent in most cases of anaphylaxis triggered by foods.9 Biphasic or 
protracted late-phase reactions may occur some hours after the initial reaction. 
Box 1: Clinical criteria for diagnosing anaphylaxis 
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Reproduced with permission from John Wiley and sons from Anaphylaxis: guidelines from the European Academy of 
Allergy and Clinical Immunology1 originally from Sampson et al 10 PEF, Peak expiratory flow; BP, blood pressure.*Low 
systolic blood pressure for children is defined as less than 70 mm Hg from 1 month to 1 year, less than (70 mm Hg 1 [2 3 
age]) from 1 to 10 years, and less than 90 mm Hg from 11 to 17 years. 
 
 
Box 2: Differential diagnoses of anaphylaxis 
Skin or mucosal  • Chronic remittent or physical urticaria and angioedema 
• Pollen-food syndrome 
Respiratory diseases   • Acute laryngotracheitis  
• Tracheal or bronchial obstruction (e.g. foreign substances, vocal        
cord dysfunction) 
• Status asthmaticus (without involvement of other organs) 
Cardiovascular 
diseases                           
• Vasovagal syncope  
• Pulmonary embolism  
• Myocardial infarction  
• Cardiac arrhythmias  
• Hypertensive crisis  
• Cardiogenic shock 
Pharmacological or 
toxic reactions             
• Ethanol  
• Histamine (e.g. scombroid fish poisoning)  
• Opiates 
Neuropsychiatric 
diseases                     
• Hyperventilation syndrome  
• Anxiety and panic disorder  
• Somatoform disorder (e.g. psychogenic dyspnea, vocal 
cord dysfunction)  
• Dissociative disorder and conversion (e.g. globus hystericus)  
• Epilepsy  
• Cerebrovascular event  
• Psychoses 
• Artifact (factitious disorder) 
• Hoigné’s syndrome  
• Coma (e.g. metabolic, traumatic) 
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Endocrinological 
diseases                     
• Hypoglycemia  
• Thyrotoxic crisis  
• Carcinoid syndrome 
• Vasointestinal polypeptide tumours  
• Pheochromocytoma 
Reproduced with permission from John Wiley and sons from Anaphylaxis: guidelines from the European Academy of 
Allergy and Clinical Immunology1 originally adapted with permission from Simons et al.2 and Muraro et al 5 
4. Epidemiology 
The epidemiology of anaphylaxis is difficult to characterise reliably because of the acute and transient 
nature of the reactions and the associated challenges in establishing prospective studies.11 12 Nonetheless, 
a number of studies have been undertaken over the last two decades. A systematic review conducted in 
2013 estimated that the incidence rates for anaphylaxis in Europe from any cause ranged from 1.5 to 7.9 
per 100,000 person years with an estimated 1 in 300 people experiencing anaphylaxis at some point in 
their lives.13 The lifetime prevalence of anaphylaxis in the UK increased from 50 to 76 per 100 000 from 
2001 to 2005.14 
There have now been a number of studies investigating hospitalisations due to anaphylaxis in the UK, 
USA and Australia, these suggesting that the incidence of anaphylaxis may be increasing.15 16 17 More 
detailed analyses of these data suggest that the most marked increase is in the under-five age group, which 
may be related to the increasing prevalence of food-allergy.18 A recent time trend study conducted in 
Australia between 2011 to 2012 supported this, finding that anaphylaxis was increasing most in the 0-4 
age group followed by children aged 5-14 years.17  
This increased incidence in anaphylaxis has not however been associated with a concomitant increased 
fatality rate.  Data from a large US epidemiological study showed the case fatality rate remained steady at 
0.3%.  Data from the UK national anaphylaxis database found that between 1992 and 2012 there was no 
increase in deaths from anaphylaxis.12, 19  
The risk of recurrence of anaphylaxis is poorly studied, but a study from Australia found that one in 12 
patients will experience a recurrent episode of anaphylaxis within a year and an estimated one in 50 will 
require treatment with adrenaline (epinephrine) and/or hospitalisation. 20 This study also investigated 
factors that contributed to the recurrent reactions and found that accidental ingestion of peanut/tree nut 
was the greatest risk factor. The combination of wheat sensitivity and exercise was also found to be an 
important risk factor. 
Important relevant epidemiological definitions have been summarised in Box 3. 
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Box 3: Epidemiological definitions 
 
 
 
 
 
 
 
 
 
 
Aetiology 
Definitions based on those proposed by Last 21 
 
 
 
Reproduced with permission from John Wiley and sons from The epidemiology of anaphylaxis in Europe: a systematic  
review 13 
 
5. Aetiology 
There are many potential risk factors, triggers and co-factors of anaphylaxis, the most important of which 
are discussed here. It is important to note that these aetiological factors may vary with age and an 
Incidence: The number of new cases of anaphylaxis that occur during a given period in a defined 
population. Incidence is divided into:  
• Incidence rate: The number of new cases of anaphylaxis that occur during a defined period per 
unit person-time.  
• Cumulative incidence: The number of new cases of anaphylaxis that occur during a given period 
per the population at risk. 
Prevalence: The proportion of a defined population known to have experienced anaphylaxis. Care is 
required in defining the appropriate denominator. This epidemiological measure is further divided into:  
• Point prevalence: the proportion of the population that has experienced anaphylaxis at a specific 
time  
• Period prevalence: the proportion of the population that has experienced anaphylaxis during a 
given period  
• Lifetime prevalence: the proportion of the population that at some point in their life will have 
experienced ana hylaxis. 
Case fatality rate: The proportion of cases of anaphylaxis that proves fatal (usually defined within a time 
period). This is also sometimes known as the case fatality ratio. 
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appreciation of these chronological changes can prove very helpful in securing the diagnosis of 
anaphylaxis.22 
 
5.1 Risk factors 
Genetic factors can predispose certain individuals to developing atopy and certain associated allergic 
disorders – for example, food allergy – which may increase the risk of anaphylaxis.23 Other allergic 
conditions such as drug and venom allergy can also manifest as anaphylaxis, but these do not appear to 
have an inherited basis. 
Environmental exposures can in some cases result in allergy and also be associated with an increased risk 
of anaphylaxis.24  Occupational groups that may be affected include beekeepers who are as a result at 
increased risk of venom allergy, healthcare professionals exposed to natural rubber latex and workers 
exposed to fruits and vegetables, drugs and chemicals.  
 
5.2 Triggers 
Foods  
Many foods can induce anaphylaxis, the most common of which are cow’s milk, hens eggs, peanuts, tree 
nuts, fish, shell-fish, soy and wheat.  The relative importance of these can however vary by geography and 
local dietary patterns.25 Anaphylaxis to food is most common in children, but can occur in people of any 
age.  
 
Insect stings 
Hymenoptera allergy is an important cause of anaphylaxis and is occasionally responsible for fatalities. 
The most common stinging insects include bees, wasps, polistes, hornets and fire ants. Venom allergy 
fatalities are more common in adults than in children.26 27 
 
Drugs/pharmacological agents 
Any drug can cause anaphylaxis, but some classes of drugs are known to illicit drug reactions more 
frequently. Further, parental administration can increase the risk of a reaction to, for example, penicillin 
and this mode of administration can also increase the severity of a reaction.28  The most common drugs 
causing allergic reactions include: 
• Antibiotics such as penicillin, sulphonamides and cephalosporins 
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• Non-steroidal anti-inflammatories (NSAIDs) 
• Chemotherapy 
• Mono-clonal antibodies 
• Contrast media.29 
 
 
Other triggers 
There are a number of other triggers, including: 
• Natural rubber latex: This was an important cause of allergy particularly in healthcare 
workers due to the use of rubber gloves, but this has reduced in countries where latex gloves 
are no longer used. Allergic reactions can range from mild to severe including anaphylaxis 
which is more common on repeated exposure to the allergen.  
• Exercise-induced anaphylaxis: This is a relatively rare cause of anaphylaxis and somewhat 
unpredictable as to the amount or intensity of exercise needed to trigger a reaction. The 
frequency of attacks can range from single to multiple in one year.30 
 
5.3 Co-factors 
Particular conditions experienced by an individual, also sometimes known as  co-factors, may increase the 
risk of developing anaphylaxis and/or a poorer outcome from a reaction (Box 4). For example, children 
with food allergy who have co-existent asthma are at increased risk of fatal respiratory compromise. 
Similarly, adults with co-existent cardiovascular disease have an increased risk of life-threatening 
cardiovascular shock if they experience anaphylaxis. 
External factors may also be important, which can make individuals more susceptible to developing 
anaphylaxis such as exercise, alcohol, drugs, infection and stress.31 These are sometimes also called 
augmentation factors. 
Box 4: Examples of risk-and co-factors of anaphylaxis 
Lifestyle factors                • Physical exertion  
• Alcohol 
 
Drugs • NSAIDs  
• ACE inhibitors  
• β-blockers 
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Patient specific factors      • Adolescence, advanced age and sex  
• Infections  
• Hormonal status  
• Psychogenic stress 
 
Pre-existing conditions     • Asthma and other IgE-dependent diseases  
• Cardiovascular disease  
• Mastocytosis and/or increased basal tryptase 
 
Reproduced with permission from John Wiley and sons from Anaphylaxis: guidelines from  
the European Academy of Allergy and Clinical Immunology 1 
6. Implications for clinical care 
A number of guidelines have been developed to support frontline clinicians to consistently deliver high 
quality anaphylaxis care.1 2 3 These are needed as evidence suggests that the management of anaphylaxis 
remains sub-optimal.32  Clinicians and departments should familiarise themselves with at least one 
guideline and have protocols in place to ensure that the key recommendations are implemented. Regular 
training should be provided to all staff who will be involved in delivering care to these patients. Audits 
should be performed to evaluate the care provided.  
 
6.1 Acute management 
Prompt recognition and diagnosis of anaphylaxis is essential.  The treatments used can be divided into 
first- and second-line interventions. 
 
First-line intervention 
All guidelines agree that the first-line treatment for anaphylaxis is adrenaline,33 which should be  
administered intramuscularly into the mid outer thigh without delay.29 34 Fatality register studies have 
found that a delay in the administration of adrenaline increases the risk of death; also of relevance is that 
predicting the severity of a reaction from its initial manifestations may prove difficult.35 36 Adrenaline may 
need to be repeated at five minute intervals if the patient is not improving or symptoms recur. The easiest 
form of administering adrenaline is with a pre-loaded auto-injector. If adrenaline is drawn up it should be 
administered at a dose of 1mg/ml at a dose of 0.01ml/kg of body weight to a maximum total dose of 
0.5ml.5 Intravenous adrenaline should only be administered by those with experience in this – typically 
intensive care unit (ICU) clinicians – and with appropriate facilities for cardiac monitoring.    
The safety profile of adrenaline is excellent and prompt administration can be life-saving. Even in the 
elderly and patients with cardiovascular disease the benefits of using adrenaline far out-weigh the risks in 
an anaphylactic reaction.2 There are therefore no absolute contraindications to the use of adrenaline. 
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Second-line interventions 
Second-line treatment involves removal of the trigger if possible – for example, a bee sting, food from the 
mouth or discontinuing IV medication.  It is important to lie the patient down unless they are 
experiencing respiratory difficulty in which case they should be sitting. This is important to minimise the 
risk of empty ventricle syndrome. In addition to the adrenaline, which as noted above may need to be 
repeated, H1-anti-histamines, corticosteroids and beta-2 agonists should be considered. Use of second-line 
agents are not life-saving, but may reduce other features of anaphylaxis and these may also reduce the risk 
of biphasic and protracted reactions.37 38 Patients should then be monitored for up to 12 hours after 
recovery in case they develop a biphasic reaction, where symptoms initially resolve and then return.39 
Patients should be discharged with an adrenaline auto-injector and advise on when and how to use it if 
there is a risk of a recurrent reaction.  
 
Box 5: Checklist for the acute management of anaphylaxis 
 
 
 
 
 
 
Reproduced with permission from John Wiley and sons from Anaphylaxis: guidelines from the European Academy of 
Allergy and Clinical Immunology1 
 
6.2 Longer-term management 
Referral and allergen avoidance 
All patients with a first episode of anaphylaxis should be referred to a specialist for further evaluation. 
The mainstay of longer-term care is identification of the trigger and any co-factors and providing detailed 
advice on how to avoid these allergic and/or other triggers. This will typically involve skin prick testing 
and/or specific-IgE testing in suspected allergic reactions, and this may in some case also involve 
challenge tests in carefully controlled and monitored clinical settings.  All those at risk of further 
anaphylaxis should be issued an adrenaline auto-injector pen and it is vitally important that they have 
1. Stay with patient 
2. Look for signs of anaphylaxis 
3. Administer adrenaline if signs of anaphylaxis 
4. Repeat adrenaline as necessary 
5. Other treatments as indicated (e.g. oxygen, beta-2 agonist, fluids, antihistamine, corticosteroid) 
6. Look for trigger (e.g. food, drug, venom) 
Adrenaline is effective for all symptoms 
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received training on when and how to use their auto-injector. Training devices are readily available from 
the manufacturers and training videos are freely accessible.40 41  
 
Managing co-existent disease 
It is important to ensure that any co-existent asthma and/or cardiovascular disease is/are optimally 
controlled as uncontrolled disease puts patients at increased risk of poor outcomes. Avoid prescribing 
angiotensin converting enzyme (ACE) inhibitors and beta-blockers. This is because ACE inhibitors 
prevent the normal physiological response of angiotensin release to compensate for fluid loss which often 
occurs in anaphylactic shock hence compounding the effects of the reaction.42 Patients on beta-blockers 
may be at an increased risk of a more severe anaphylaxis as beta-blockers, whether given topically or 
orally, can prevent the effect of adrenaline at the beta-adrenergic receptor thus reducing its effect 43 44  
 
Information and communication 
Advise should be given on wearing relevant identification jewellery e.g. MedicAlert 
(www.medicalert.co.uk) and contact information needs to be provided for anaphylaxis patient support 
groups. We advise that patients/parents inform work/carers/schools, etc. so that they can arrange to 
have access to adrenaline auto-injectors for the named patient. Clearly noting the diagnosis of 
‘Anaphylaxis’ in all paper and electronic health records is important to ensure effective communication 
across care transitions. It is particularly important that all staff involved in potentially high-risk situations 
such as vaccinations, anaesthesia and immunotherapy are trained in the recognition and management of 
anaphylaxis.  
 
Anaphylaxis management plans 
The patient/carer should be provided with a tailored anaphylaxis management plan (see Box 6), which 
includes instructions on managing allergy in different contexts.  Relevant information may include:                         
• Allergen avoidance measures (where possible)  
• How to recognise anaphylaxis 
• When to use their adrenaline auto-injector 
• How to use their adrenaline auto-injector 
• What to do next.  
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Box 6: Example of an individualised management plan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced with permission from John Wiley and sons from Anaphylaxis: guidelines from the European Academy of 
Allergy and Clinical Immunology 8 
 
Allergen immunotherapy 
If you think you/your child/other are having an anaphylactic reaction after possible contact with an 
allergic trigger. or after possible contact with an allergic trigger, any of the following symptoms may 
indicate that you/your child/other is experiencing an anaphylactic reaction:  
• Airway problems: swelling of tongue, swelling/tightness in the throat, difficulty swallowing, 
difficulty talking and/or hoarse voice  
• Breathing problems: difficulty breathing, noisy breathing, wheeze and/or persistent cough  
• Consciousness: feeling faint, dizziness, confused state or loss of consciousness/pale and floppy 
(young children)  
Then:  
1. Immediately administer adrenaline auto-injector into the upper outer thigh  
2. Call an ambulance stating that the patient is having an anaphylactic reaction  
3. Lay person having the reaction down (with legs up if possible); if there is difficulty in breathing, 
allow them to sit up but not stand  
4. If no improvement after 5 minutes, administer a second adrenaline auto-injector. 
When in doubt, administer the adrenaline auto-injector.  
This is only one example of an anaphylaxis action plan. The plan should be individualized, for example, 
patients with previous rapid onset life-threatening anaphylaxis may be instructed to use their self-
injectable adrenaline earlier in the development of any subsequent allergic reaction 
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Allergen immunotherapy (AIT) is a potential disease-modifying treatment that can be used for venom 
allergy and food allergy, with encouraging results.45 46 This mode of treatment is most well established for 
venom allergy. Patients who have experienced anaphylaxis will often feel anxious regarding a recurrence 
and have considerable psychological morbidity which is further heightened from the continuous carriage 
of an adrenaline auto-injector. Venom immunotherapy has been shown to improve patient’s quality of 
life.47  
AIT for food allergy is a developing area and offers the first potentially curative approach to managing  
this condition. Foods for which this is available and have been shown to be effective in terms of 
desensitisation (i.e. the ability to safely consume foods containing the allergen in question whilst on AIT 
are cow’s milk, hens eggs and peanut.46 It remains to be determined whether tolerance (i.e.  the ability to 
consume the foods in question post-discontinuation of AIT) can be induced. This therapy is most 
effective in children rather than adults and needs to be conducted by specialists with full resuscitative 
equipment available. The risk of systemic side-effects is increased by taking AIT so specialist input in 
selecting the appropriate patients is required.  
 
Follow-up 
Regular follow-up should be considered to reassess risk, review the need for auto-injector training and in 
children the dose of adrenaline, optimise treatment and ensure appropriate care co-ordination. A 
summary of the long-term management of anaphylaxis can be found in Box 7. 
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Box 7: Summary of the long term management of anaphylaxis 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced with permission from John Wiley and sons from Anaphylaxis: guidelines from the European Academy of 
Allergy and Clinical Immunology 8 
 
7. Conclusions 
Anaphylaxis is a condition associated with considerable morbidity and it may on occasions also prove 
fatal.  
8. Expert commentary: Much of this morbidity and mortality is potentially preventable through earlier 
recognition, prompt emergency treatment with adrenaline and proactively assessing and taking steps to 
reduce the risk of further reactions. Evidence-based guidelines now exist to support clinicians to provide 
consistent high quality acute and long-term anaphylaxis care.   
 
Provision of individualized management plan written clearly in simple, non-medical language; it should 
include: »personal identification data: name and address; contact details of the parents, guardian or next of 
kin, allergist, family doctor and the local ambulance service; and preferably a photograph »clear 
identification of the source of the allergens to be avoided and allergen avoidance advice »clear 
identification of any non-allergen triggers or cofactors, such as exercise, and avoidance advice 
»anaphylaxis emergency action plan Copy of plan should be kept by the patient, any caregivers, school 
staff and family doctor. 
• Provision of emergency kit with copy of anaphylaxis emergency action plan and medications for 
self-treatment, e.g. »adrenaline auto-injector for treating anaphylaxis, where appropriate »fast 
acting, non-sedating, antihistamine for treating cutaneous allergic reactions, where appropriate 
• Venom immunotherapy and desensitisation in drug allergy as appropriate. 
• Training of patients and caregivers, this should include: »instructions on appropriate allergen 
avoidance measures, including consultation with an allergy dietitian, where appropriate 
»instructions on prompt recognition of symptoms of anaphylaxis »training on when and how to 
use an adrenaline auto-injector, where appropriate reinforcement with revision at regular yearly 
intervals 
• Psychological support as required 
• Implementation of the patient’s management plan in the community (e.g. nursery, school) 
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9. 5-year view: We envisage some further developments in the underlying evidence base to help risk 
stratification and substantial additional developments in work supporting the implementation of 
recommendations from recent guidelines into routine care.  
10. Key issues 
• Anaphylaxis is responsible for considerable morbidity and it may in some cases prove fatal. 
• Acute management of anaphylaxis is centred on early recognition, prompt treatment with 
adrenaline (epinephrine) and other essential life-support measures.   
• The importance of longer-term care of patients with a history of and/or those at risk of 
anaphylaxis need to be  considered with a view to minimising the risk of further reactions and 
decreasing the severity and impact of any reactions that do occur.   
• There needs to be focused efforts to translate the recommendations from recent evidence-based 
anaphylaxis guidelines into routine clinical care. 
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